OCT 2 7 2003 304

PATENT 1694 Atty. Docket No. 925.302

I hereby certify that this paper and attribute the states Postal Service as first class mail in an envelope addressed: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 1, 2003.

Esperanza C. Licad Esperanza C. Licad

10/24/03 Date

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

de Boer, Mark et al.

Serial No.:

09/954,764

Art Unit:

1644

Filed:

September 18, 2001

Examiner:

Gambel, P.

For:

METHOD OF TREATING AN IgE-MEDIATED DISEASE IN A PATIENT

**USING ANTI-CD40 MONOCLONAL ANTIBODIES** 

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR § 1.97(c)

Commissioner for Patents Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CRF § 1.97(c), the Applicant wishes to call to the attention of the Examiner additional references on the attached Form PTO-1449, which may be considered material to the examination of the above-identified patent application. The Examiner is requested to make these citations of official record in the present application.

Pursuant to 37 CFR 1.98(d), copies of items C66-C71 on Form PTO-1449 are not enclosed because they were previously cited and/or are of record in U.S. Serial No. 09/504,505, from which priority is claimed. However, copies of items A10-A12, B11-B15, and C72-75 are provided because they were not of record. If the Examiner wishes a copy of any other reference, please advise and it will be provided. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the documents have been reviewed and made of record.

Pursuant to 37 CFR §1.17(p), a check in the amount of \$180 is enclosed to cover the fee associated with this filing.

The Commissioner is hereby authorized to credit any overpayments or charge any additional fees in connection with this Information Disclosure Statement to Deposit Account No. 03-1664.

Respectfully submitted,

October 21,2003

By: Stoc/10-4.

Attorney for Applicants

Reg. No. 41,576

CHIRON CORPORATION Intellectual Property P.O. Box 8097 Emeryville, California 94662-8097 (510) 923-2585 (510) 655-3542 (fax)

SHEET 1 OF 2

FORM PTO-1449 (Modified)	U.S. Dept. of Commerce Patent and Trademark Office	Auy. Solke No 925.302	Serial No.: 09/954,764
INFORMATION DISCLOSURE CITATION		Applicants: de Boer, M. et al.	
(Use several sheets if necessary)		Filing Date: 09/18/2001	Group: 1644

## U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	A10	5,674,492	10/07/97				
	All	5,801,227	09/01/98				
	A12	5,916,560	06/29/99				

## FOREIGN PATENT DOCUMENTS

	Document Number	Publ. Date	Country	Class	Subclass	Trans- Yes	lation No
B11	EP 0 585 943 B1	02/1998	EP				
B12	WO 00/16801	03/2000	PCT				
B13	WO 01/24823	04/2001	PCT				
B14	WO 01/34649	05/2001	PCT				
B15	WO 01/83755	11/2001	PCT				

OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)

C66	Dharakul, T. et al., "Immunization with Baculovirus-Expressed Recombinant Rotavirus Proteins VP1, VP4, VP6, and VP7 Induces CD8+ T Lymphocytes that Mediate Clearance of Chronic Rotavirus Infection in SCID Mice," J. Virol. 65(11): 5928-5932, 1991.
C67	Miller, L.K., "Chapter 23: Baculoviruses for Foreign Gene Expression in Insect Cells," in Vectors: A survey of Molecular Cloning Vectors and Their Uses, (Rodriguez, R.L. et al., eds., Butterworths 1988, pp. 457-465.
C68	Sekine, H. et al., "Expression of Human Papillomavirus Type 6b E2 Gene Product with DNA-Binding Activity in Insect (Bombyx Mori) cells using a Baculovirus Expression Vector," Gene 65(2): 187-193, 1988.
C69	Smith, G.E. et al., "Modification and Secretion of Human Interleukin 2 Produced in Insect Cells by a Baculovirus Expression Vector," <i>Proc. Natl. Acad. Sci.</i> USA 82: 8404-8408, 1985.
C70	Takehara, K. et al, "Co-expression of the Hepatitis B Surface and Core Antigens Using Baculovirus Multiple Expression Vectors," J. Gen. Virol. 69 (Pt. 11): 2763-2777, 1988.
C71	Urakawa, T. et al., "Synthesis of Immunogenic, but Non-Infectious, Poliovirus Particles in Insect Cells by a Baculovirus Expression Vector," J. Gen. Virol. 70 (Pt. 6): 1453-1463, 1989.

Examiner	Date Considered

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 2 OF 2

FORM PTO-1449 (Modified)	U.S. Dept. of Commerce Patent and Trademark Office	Atty. Docket No. 2015 TE POLITICATE OF THE POLIT	Serial No.: 09/954,764	
INFORMATION DISCLOSURE CITATION		Applicants: de Boer, M. et al.		
(Use several sheets if necessary)		Filing Date: 09/18/2001	Group: 1644	

OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.) C72 Bajorath, J. et al., "Construction and Analysis of a Detailed Three-Dimensional Model of the Ligand Binding Domain of the Human B Cell Receptor CD40", Proteins: Structure, Function and Genetics, 27: 59-70, 1997. C73 Barr, T.A. et al., "Functional Activity of CD40 Antibodies Correlates to the Position of Binding Relative to CD154, Immunology, 102: 39-43, 2001. C74 Ellmark, P. et al., "Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library, Immunology 106: 456-463, 2002. C75 Hager, A.C. et al., "Affinity and Epitope Profiling of Mouse Anti-CD40 Monoclonal Antibodies", Scandanavian Journal of Immunology, 57, 517-524, 2003.

Examiner	Date Considered

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.